Sanofi has shared data from the phase 3 HERCULES trial that could rescue its multiple sclerosis (MS) drug candidate ...

In this morning’s readout from Novo's phase 2 trial of monlunabant in 243 people with obesity and metabolic syndrome, it ...

Edgewise Therapeutics's hypertrophic cardiomyopathy (HCM) asset has started off with a bang after early safety data sent the ...

Masimo’s long-running proxy fight has come to a close, at least for now. | Masimo’s long-running proxy fight has come to a ...

Slow enrollment in a key clinical trial has driven Genfit to rework the protocol to try to keep the study on track. | Slow ...

Warren Biddle hit the exit from his role as SVP, global head of commercial at Gilead’s CAR-T unit Kite Pharma to take on the ...

A surgeon makes small incisions in the eye, sucks out the cloudy lens and replaces it with an artificial lens implant.

GC Therapeutics has entered gameplay with the mission of unlocking a new generation of cell therapies, uploading with $75 ...

Novo Nordisk is continuing its push into genetic medicines, agreeing to pay NanoVation Therapeutics up to $600 million to ...

Vanda Pharmaceuticals has failed to persuade the FDA to approve its gastroparesis candidate on the strength of a phase 3 ...

The update stated that the implant’s cobalt-chromium alloy carries an increased risk of femur fractures following a procedure ...

Athira Pharma has been on a bumpy road in recent years, and, now, the company is restructuring and shedding weight to try to keep the journey going.  | Just a couple of weeks after announcing that its ...